Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Summary
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Timeline
- Start
- 2019-03-25
- Primary completion
- 2025-03-25
- Completion
- 2025-03-25
Outcome
Mixed primary results
registry MEDIAN Ramipril: 0.00 (-0.71 to 0.59) Change in standardized score NCT03475186 ↗
registry MEDIAN RTOG 0825 Control Arm: -0.60 (-1.60 to 0.00) Change in standardized score NCT03475186 ↗
registry analysis (superiority test); Ramipril vs RTOG 0825 Control Arm; p = 0.04; NCT03475186 ↗
registry analysis (superiority test); Ramipril vs RTOG 0825 Control Arm; p = 0.33; NCT03475186 ↗
registry analysis (superiority test); Ramipril vs RTOG 0825 Control Arm; p = 0.29; NCT03475186 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramipril | Small molecule | 2.5 mg | Oral |
| Subject | Ramipril | Small molecule | 5 mg | Oral |